Sep 16,2020

DreaMed Diabetes Gets $5 Million Grant to Test Virtual Diabetes Care Solutions

DreaMed Diabetes expertise in the diabetes management space has positioned the company to receive a $5 million dollar grant as part of a research study to determine the effectiveness of virtual diabetes care. Funding for the research study comes from The Leona M. and Harry B. Helmsley Charitable Trust and will focus on determining if the virtual clinic model improves clinical and psychological outcomes for people with diabetes. DreaMed, with partner Cecilia Health, will provide a multi-faceted platform to fully evaluate the effectiveness of virtual clinics using DreaMed’s technology.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Sep 25,2020

Hygieia Raises $1.7M Debt Finance

Hygieia received $1.7 million funding in a debt finance according to the SEC form registered.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Oct 08,2020

Lark Health Raises $55 Million Series C to Bring A.I.-Driven Chronic Conditions Care to More People

Lark Health today announced it has closed a $55 million Series C funding round led by King River Capital, as well as a $15 million venture debt credit facility with Trinity Capital and Bridge Bank. The round also includes new investors Franklin Templeton, SteelSky Ventures, and Olive Tree Capital; and existing Lark investors Lightspeed Ventures, Asset Management Ventures, Dr. Jonathan Fielding of UCLA Fielding School of Public Health, and Weili Dai, co-founder of Marvell. Lark has raised a total of over $100 million in equity and debt funding to date.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Oct 09,2020

Lark Health Raises $15 Million Debt Financing with Trinity Capital and Bridge Bank

Lark Health today announced it has closed a $55 million Series C funding round led by King River Capital, as well as a $15 million venture debt credit facility with Trinity Capital and Bridge Bank. The round also includes new investors Franklin Templeton, SteelSky Ventures, and Olive Tree Capital; and existing Lark investors Lightspeed Ventures, Asset Management Ventures, Dr. Jonathan Fielding of UCLA Fielding School of Public Health, and Weili Dai, co-founder of Marvell. Lark has raised a total of over $100 million in equity and debt funding to date.

FUNDING DEBT FINANCE
View Analyst & Ambassador Comments
Go to original news
Nov 10,2020

Carbon Health raises $100 million with plans to expand pop-up clinics ahead of COVID-19 vaccination programs

Carbon Health has raised a $100 million Series C funding round, led by Dragoneer Investment Group and including participation from prior investors Brookfield Technology Partners, DCVC and Builders VC. This funding will be used to help the SF-based healthcare provider startup continue to expand its nationwide footprint, including with the opening of 100 pop-up clinics planned for 20 markets across the U.S.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Nov 20,2020

Voluntis Successfully Completes a Capital Increase of €5.9 Million and Finalizes the Financing of Its Strategic Roadmap

Voluntis announces today the completion of a capital increase without preferential subscription rights exclusively reserved to the category of investors defined below for a total amount of €5.9 million. The securities were subscribed by quality European investors, most of them specialized in the healthcare sector, including Debiopharm Innovation Fund, Corporate fund of Swiss company Debiopharm, and Indigo, the holding company of M. Eric Carreel, Chairman & co-founder of Withings, which strengthened its position.

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Nov 30,2020

Habitual Health secures £325k Seed investment led by Seedcamp

Habitual, the UK’s first fully digital diabetes prevention and reversal programme, has today announced a raise of £325,000 in funding, taking its total to £575,000, to support its public launch in 2021.

FUNDING PRE SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 18,2021

Senseonics Holdings Announces $50.0 Million Bought Deal Offering of Common Stock

Senseonics Holdings today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 25,974,026 shares of common stock of the Company at a public offering price of $1.925 per shareThe gross proceeds of the offering are expected to be approximately $50.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses and excluding the exercise of the underwriter’s option to purchase additional shares.

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Jan 27,2021

DARIOHEALTH ANNOUNCES ACQUISITION OF LEADING DIGITAL MUSCULOSKELETAL COMPANY UPRIGHT TECHNOLOGIES AND $70 MILLION FINANCING

DarioHealth Corp. announced today the signing of a definitive agreement to acquire digital musculoskeletal (MSK) company Upright Technologies Ltd. in a stock transaction. Dario has concurrently announced definitive agreements with a syndicate of highly regarded healthcare institutional investors to raise $70 million through a private placement of its common stock priced at the market pursuant to Nasdaq rules. Dario has executed securities purchase agreements for the sale of an aggregate of 3,278,688 shares of its common stock at a purchase price of $21.35 per share. Dario intends to use the net proceeds from the offering for general corporate purposes.

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Feb 11,2021

Nemaura Medical Secures $20 Million Non-Dilutive Non-convertible Loan to Accelerate Growth

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces it has secured a $20 million non-dilutive, non-convertible loan that was secured by Company assets. The loan does not include warrants or other equity securities. Nemaura Medical CEO, Dr. Faz Chowdhury said, “We appreciate the continued strong support from our lender, Chicago Venture Partners.”

FUNDING POST-IPO DEBT
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES